Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.04 USD | +3.39% | +6.23% | +47.91% |
Financials (USD)
Sales 2024 * | 161M | Sales 2025 * | 413M | Capitalization | 3.25B |
---|---|---|---|---|---|
Net income 2024 * | -352M | Net income 2025 * | -245M | EV / Sales 2024 * | 19.3 x |
Net cash position 2024 * | 133M | Net cash position 2025 * | 251M | EV / Sales 2025 * | 7.27 x |
P/E ratio 2024 * |
-8.97
x | P/E ratio 2025 * |
-16.1
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | +3.31% | ||
1 week | +6.10% | ||
Current month | -18.96% | ||
1 month | -15.36% | ||
3 months | +44.70% | ||
6 months | +224.59% | ||
Current year | +47.72% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 1 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 12.04 | +3.39% | 2 957 588 |
24-04-26 | 11.64 | +0.87% | 2,489,561 |
24-04-25 | 11.54 | -1.45% | 3,398,958 |
24-04-24 | 11.71 | -1.26% | 2,932,120 |
24-04-23 | 11.86 | +4.77% | 3,895,064 |
Delayed Quote Nasdaq, April 29, 2024 at 11:52 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.72% | 3.25B | |
-19.16% | 10.82B | |
-32.57% | 2.11B | |
-17.21% | 2.08B | |
-26.10% | 1.48B | |
+19.16% | 1.02B | |
-4.37% | 733M | |
-32.57% | 391M | |
-44.18% | 383M | |
+13.32% | 332M |
- Stock Market
- Equities
- IOVA Stock